MicroRNA polymorphisms as markers of risk, prognosis and treatment response in hematological malignancies

https://doi.org/10.1016/j.critrevonc.2014.08.006Get rights and content

Highlights

Abstract

MicroRNA dysregulation is a common event in hematological malignancies. Apart from genomic and epigenetic alterations, miRNA networks may be disturbed by polymorphisms in the miRNA regulatory pathway (miRSNPs). In this review we provide an overview of three categories of miRSNPs: (1) SNPs in genes involved in miRNA biogenesis and processing; (2) SNPs in miRNA genes; and (3) SNPs in miRNA binding sites in target genes and discuss their potential role as markers of disease risk, prognosis and treatment response in hematological cancers. Although so far only the tip of the iceberg has been touched, studies of polymorphisms in the miRNA regulatory pathways have already provided some clues for the mechanisms of miRNA dysregulation in cancer and open new perspectives in the management of hematological malignancies.

Introduction

MicroRNAs (miRNAs) are a class of small (∼22 nucleotide) non-coding RNAs that have emerged as key factors in the posttranscriptional regulation of gene expression. To date more than 2500 mature human miRNAs have been identified [1] and they are predicted to regulate over 60% of human protein-coding genes [2]. MiRNA-mediated regulatory networks can be very complex as one miRNA may potentially target several mRNAs, and a given mRNA may be regulated by several miRNAs. MiRNAs recognize their specific target transcripts by pairing with complementary sequences in the mRNA, which are usually located in the 3′ untranslated region (3′UTR), but can also be present in the 5′UTR or in the coding region. The minimum requirement is complementarity of the nucleotides 2–7 of the miRNA (so called ‘seed region’) but the miRNA–mRNA interaction can be enhanced by pairing of additional nucleotides of the miRNA [3]. This binding usually results in translational repression and/or degradation of the target mRNA but pairing of a miRNA with sequences located in the 5′UTR or the promoter can induce translation and transcription, respectively [4], [5].

MiRNA genes are located in introns of protein-coding genes or form independent clusters in the genome. In the process of miRNA biogenesis the primary long transcript (pri-miRNA) generated by RNA polymerase II is first processed by the Drosha complex to release a hairpin-structured miRNA precursor (pre-miRNA). Pre-miRNAs are exported to the cytoplasm by Exportin-5, where they undergo cleavage by Dicer to produce the mature double-stranded 22 nt miRNA. One strand is loaded into an Ago protein, a component of the RNA-induced silencing complex (RISC) and guides RISC to the target mRNAs leading to repression of translation or mRNA degradation [6], [7].

MiRNAs have been shown to control a wide variety of biological processes, including development, proliferation, metabolism, apoptosis, hematopoiesis and differentiation [8], and disruption of miRNA regulatory networks has been linked with various diseases, including cancer [9]. MiRNAs can act as both oncogenes and tumor suppressors. Examples of oncogenic miRNAs that are amplified or overexpressed in cancers include miR-17-92 cluster, miR-21, miR-155 and miR-372/373, while tumor suppressor miRNAs commonly deleted or with reduced expression in cancers are represented by miR-15a and miR-16-1, miR-34 family, let-7 family and miR-29 [10]. It has become evident that miRNAs play crucial role in normal hematopoiesis by controlling the differentiation of hematopoietic stem cells, while deregulation of miRNAs in hematopoietic cells has been linked to hematological malignancies [11], [12]. Leukemias and lymphomas are characterized by aberrant miRNA expression profiles [13], [14] and these specific miRNA expression signatures can accurately discriminate different leukemia subtypes and often have great prognostic significance [15], [16], [17], [18], [19]. Apart from genomic and epigenetic alterations, deregulation of the miRNA networks may result from polymorphisms in the miRNA regulatory pathway (miRSNPs). In the recent years several studies have shown association of miRSNPs with cancer and other diseases [20], [21]. MiRSNPs can be classified into three categories: (1) SNPs in genes involved in miRNA biogenesis and processing; (2) SNPs in miRNA genes; and (3) SNPs in miRNA-binding sites in target genes [22]. Their relevance for cancer can be considered in terms of risk of developing a disease, prognosis for the disease progression and survival, and treatment response.

This review focuses on miRSNPs in hematological malignancies and discusses their potential contribution to the development of blood cancers and their role as prognostic factors and markers of treatment outcome.

Section snippets

SNPs in genes involved in miRNA biogenesis and processing

Polymorphisms affecting expression or function of proteins involved in the biogenesis of miRNAs may interfere with miRNA regulatory networks in the cell. This class of miRSNPs would likely have the broadest impact on the miRNA-mediated regulation as they could affect global miRNA biogenesis and deregulate the whole microRNAome of the cell, affecting expression of all genes targeted by miRNAs (Fig. 1A). Several potentially functional polymorphisms in genes involved in various steps of miRNA

SNPs in miRNA genes

Polymorphism in pri- and pre-miRNAs can influence their processing, whereas polymorphisms in mature miRNAs can affect their binding to target transcripts. Also SNPs in promoters of miRNA genes or miRNA host genes may have impact on the expression of miRNAs. This class of miRSNPs would possibly have quite broad impact for the cell, as any miRNA can potentially regulate many genes involved in various processes (Fig. 1B).

SNPs in miRNA-binding sites in target genes

Polymorphisms in miRNA-binding sites in target genes may alter the strength of miRNA–mRNA interactions, thus deregulating protein levels. This class of miRSNPs would likely have the most limited impact for the cell, affecting only expression of the gene harboring the SNP. However, indirect effect of SNPs in miRNA-binding sites may be much wider as they will influence the pool of miRNAs available for other transcripts that are also regulated by a given miRNA (Fig. 1C). This could lead to

Conclusions

In the recent years it has become evident that microRNAs play fundamental role in the regulation of gene expression and that disruption of miRNA regulatory networks can lead to cancer. Polymorphisms in miRNA pathways may interfere with miRNA expression and function, which in turn can affect expression of several genes.

This review summarizes the growing knowledge in the field of miRNA polymorphisms (miRSNPs) in hematological malignancies. From the presented data, miRSNPs emerge as potential

Conflict of interest statement

The author declares no conflict of interest.

Reviewers

Dr Africa Garcia-Orad, University of the Basque Country, Genetics, Physical Anthropology/Animal Physiology, Barrio Sarriena s/n, ES-48940 Leioa, Bizhaia, Spain.

Dr Alfons Navarro, Molecular Oncology and Embryology Laboratory, Human Anatomy Unit, School of Medicine, University of Barcelona, IDIBAPS, Barcelona, Spain.

Acknowledgment

This work was supported by Ministry of Science and Higher Education grant No. N N401 570740.

Agnieszka Dzikiewicz-Krawczyk, Ph.D., is a postdoctoral research fellow at the Institute of Human Genetics, Polish Academy of Sciences, Poland. Her current research focuses on the role of microRNAs and long non-coding RNAs in leukemias.

References (65)

  • S. Vinci et al.

    Genetic and epigenetic factors in regulation of microRNA in colorectal cancers

    Methods

    (2013)
  • L. Salmena et al.

    A ceRNA hypothesis: the Rosetta Stone of a hidden RNA language

    Cell

    (2011)
  • Y. Xie et al.

    A miR-SNP of the KRT81 gene is associated with the prognosis of non-Hodgkin's lymphoma

    Gene

    (2014)
  • B. Yang et al.

    A polymorphism at the microRNA binding site in the 3′ untranslated region of C14orf101 is associated with non-Hodgkin lymphoma overall survival

    Cancer Genet

    (2014)
  • Y. Li et al.

    Single nucleotide variation in the TP53 3′ untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program

    Blood

    (2013)
  • B. Falini et al.

    Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity

    Blood

    (2011)
  • A. Kozomara et al.

    miRBase: annotating high confidence microRNAs using deep sequencing data

    Nucleic Acids Res

    (2014)
  • R.C. Friedman et al.

    Most mammalian mRNAs are conserved targets of microRNAs

    Genome Res

    (2009)
  • R.F. Place et al.

    MicroRNA-373 induces expression of genes with complementary promoter sequences

    Proc Natl Acad Sci U S A

    (2008)
  • T. Treiber et al.

    Regulation of microRNA biogenesis and function

    Thromb Haemost

    (2012)
  • C.M. Croce

    Causes and consequences of microRNA dysregulation in cancer

    Nat Rev Genet

    (2009)
  • S. Yendamuri et al.

    The role of microRNA in human leukemia: a review

    Leukemia

    (2009)
  • S. Babashah et al.

    Aberrant microRNA expression and its implications in the pathogenesis of leukemias

    Cell Oncol (Dordr)

    (2012)
  • G.A. Calin et al.

    A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia

    N Engl J Med

    (2005)
  • V. Fulci et al.

    Characterization of B- and T-lineage acute lymphoblastic leukemia by integrated analysis of MicroRNA and mRNA expression profiles

    Genes Chromosomes Cancer

    (2009)
  • D. Schotte et al.

    MicroRNA characterize genetic diversity and drug resistance in pediatric acute lymphoblastic leukemia

    Haematologica

    (2011)
  • E. San José-Enériz et al.

    MicroRNA expression profiling in Imatinib-resistant chronic myeloid leukemia patients without clinically significant ABL1-mutations

    Mol Cancer

    (2009)
  • P.J. Mishra et al.

    MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and individualized medicine

    Pharmacogenomics

    (2009)
  • F.J. Song et al.

    Single-nucleotide polymorphisms among microRNA: big effects on cancer

    Chin J Cancer

    (2011)
  • A. Gutierrez-Camino et al.

    Non-coding RNAs-related polymorphisms in pediatric acute lymphoblastic leukemia susceptibility

    Pediatr Res

    (2014)
  • E. López-López et al.

    Pharmacogenetics of MicroRNAs and MicroRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia

    PLOS ONE

    (2014)
  • X. Li et al.

    Polymorphisms in MicroRNA-related genes are associated with survival of patients with T-cell lymphoma

    Oncologist

    (2014)
  • Cited by (20)

    • miRNAs mediated drug resistance in hematological malignancies

      2022, Seminars in Cancer Biology
      Citation Excerpt :

      Several other studies have demonstrated that miRNA dysregulation is deeply associated with the pathogenesis and the progression of hematological malignancies [87,89,93–95]. This miRNA dysregulation in tumors is believed to be mainly due to four causes that will be further explained below: (i) genetic/cytogenetic alterations [60,94], (ii) epigenetic modifications [96], (iii) single nucleotide polymorphisms (SNPs) in miRNAs regulatory networks (miRSNPs) [87,97], and (iv) extracellular factors/components associated with the modulation of miRNAs dysregulation [98,99]. Regarding the (i) genetic/cytogenetic alterations, the fact that a great number of miRNA genes (over 50 % of the described miRNAs) are located in cancer-associated genomic regions or in fragile sites makes these genetic/cytogenetic alterations an important possible cause for miRNAs dysregulation in hematological tumors [60].

    • Genetic Association Analysis Implicates Six MicroRNA-Related SNPs With Increased Risk of Breast Cancer in Australian Caucasian Women

      2021, Clinical Breast Cancer
      Citation Excerpt :

      To date, altered regulation of miRNAs and the association of SNPs in miRNA genes13,20,21 have been identified in the development and progression of numerous cancers, including BC.20,22 MicroRNA SNPs (miRSNPs) are a novel class of functional polymorphisms that may have both preventive and adverse effects on cancer susceptibility.23,24 For example, the presence and location of a miRSNP can result in loss of miRNA-mediated drug target gene regulation conferring drug resistance.25

    • The role of miRNA-196a2 genotypes in the susceptibility of acute lymphoblastic leukemia in Egyptian children

      2021, Gene Reports
      Citation Excerpt :

      Their dysregulation is involved in human diseases including cancer, miRNAs could play roles in the cancer development, contribute in the process of tumor immunity and can be used as biomarkers for the diagnosis and prognosis (He et al., 2020). Multiple studies have shown association of miRNA SNPs with cancer and other diseases (Dzikiewicz-Krawczyk, 2015). Multiple evidences in the recent years have shown that miRNA-196a2 (rs11614913) may play a role in the development of many cancer types, like lung, gastric, breast, colorectal, gallbladder cancer and head and neck cancer and prostate cancers (Chen et al., 2020; Liu et al., 2018).

    • Correlations of pri-Let-7 gene polymorphisms with the recurrence and metastasis of primary liver cancer after transcatheter arterial chemoembolization

      2018, Pathology Research and Practice
      Citation Excerpt :

      The C/C or A/C variant in XPO5 rs11077 was also studied in non-small cell lung cancer, which indicated that the C allele was related to better patient prognosis and treatment response. Additionally, the A allele in small cell lung cancer, was associated with a longer survival time [37]. In conclusion, our findings confirmed that a worse prognosis is found in patients with PLC who carry the AC + CC genotype of pri-let-7a-2 rs629367 after TACE in comparison with patients with the AA genotype This suggests that the pri-let-7 rs629367 SNP could be used as a predictor for the recurrence and metastasis of PLC in patients who have undergone TACE.

    • The Role of Exportin-5 in MicroRNA Biogenesis and Cancer

      2018, Genomics, Proteomics and Bioinformatics
      Citation Excerpt :

      Furthermore, multivariate analysis indicates that miR-SNP rs11077 of XPO5 gene is an independent prognostic marker to predict survival for advanced SCLC and NSCLC patients [36,37]. Other studies have also reported that patients with AA genotype of rs11077 exhibit an increased risk of esophageal cancer and gastric cancer [38,39], and are associated with short overall survival in multiple myeloma (after autologous stem cell transplantation), Hodgkin’s lymphoma, and renal cell carcinoma [40–42]. The rs11077 associated miRNAs need further investigation.

    View all citing articles on Scopus

    Agnieszka Dzikiewicz-Krawczyk, Ph.D., is a postdoctoral research fellow at the Institute of Human Genetics, Polish Academy of Sciences, Poland. Her current research focuses on the role of microRNAs and long non-coding RNAs in leukemias.

    View full text